Mark Chao, TenSixteen CEO
January 27, 2022 09:00 AM EST
Financing
Startups

With Forty Sev­en co-founder at the helm, new biotech spin­out launch­es to tar­get mu­ta­tions po­ten­tial­ly linked to nu­mer­ous dis­eases

Paul Schloesser

Associate Editor

Mark Chao is go­ing back in­to biotech — and his new com­pa­ny, launched this morn­ing, is go­ing af­ter mys­te­ri­ous mu­ta­tions in the blood and how they …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times